LOS ANGELES, Sept. 11 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Tapestry Pharmaceuticals (Nasdaq: TPPH). Ross Silver, Director of Research for Vista Partners stated, "Tapestry's lead compound TPI-287 showed promise in Phase I trials. We were particularly encouraged by activity in patients with pancreatic cancer as no other taxanes have been approved for use in this difficult to treat cancer." Vista Partners provides independent equity research for institutional and individual investors, with a focus on publicly traded small capitalization companies. For more information and to download the report; please visit the Vista Partners website at http://www.vistap.com.
Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. For more information about Tapestry and its technologies, visit Tapestry's website at http://www.tapestrypharma.com.
Vista Partners LLC
|SOURCE Vista Partners|
Copyright©2007 PR Newswire.
All rights reserved